Prof. Zhijie Wang 王志杰
Chief Physician, Professor
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Personalized diagnosis and treatment of lung cancer, thymoma, thymic carcinoma, mesothelioma, and sarcoma.
Dr. Wang holds a doctorate in oncology and is a professor and chief physician at the Cancer Hospital, Chinese Academy of Medical Sciences. Trained at M.D. Anderson Cancer Center, Dr. Wang serves as a master’s supervisor at Peking Union Medical College. The doctor has led multiple national and provincial research projects and authored nearly 30 SCI-indexed papers.
Professional roles
- Director, Chinese Society of Clinical Oncology (CSCO)
- Standing Committee Member, CSCO Non-Small Cell Lung Cancer Expert Committee
- Standing Committee Member, CSCO Young Experts Committee
- Vice Chair, Lung Cancer Professional Committee Youth Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Wang Zhijie). Papers usually list the name as Zhijie Wang or Wang Z.
Selected publications
195 papers on PubMed matched by name and affiliation; 51 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Endocr Soc, 2026 (senior author): Colorectal neuroendocrine neoplasm organoids reveal the potential therapeutic value of targeting BRAF mutations. PubMed 42694446
- Oncol Ther, 2026 (first author): First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307. PubMed 41811656
- Eur J Surg Oncol, 2025 (first author): A retrospective analysis of 44 diminutive rectal neuroendocrine neoplasms that were not suitable for local treatment. PubMed 40738072
- Chin Med J Pulm Crit Care Med, 2025 (senior author): Burden of chemotherapy-induced myelosuppression (CIM) in Chinese patients with extensive-stage small cell lung cancer (ES-SCLC): A retrospective real-world study. PubMed 41114079
- Nat Commun, 2025 (senior author): Author Correction: Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy. PubMed 39994256
- Future Oncol, 2025 (first author): A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC). PubMed 39628302
- Heliyon, 2025 (senior author): Construction and evaluation of the prediction model for advanced disease in well-differentiated colorectal neuroendocrine neoplasms less than 2 cm in diameter. PubMed 39801965
- Pneumonia (Nathan), 2024 (senior author): Pneumonic-type lung adenocarcinoma with KRAS G12V mutation and sustained response to Afatinib. PubMed 38659041
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion